Biomarin Pharmaceutical Inc. - Registered Shares
BMRN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.76B
Close$
$96.61
69.2% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
69.2% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$156.91174.7% upside
Current Fair Value
174.7% upsideUndervalued by 174.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $11.76 Billion |
|---|---|
| Enterprise Value | $15.09 Billion |
| Earnings per Share | $1.82 |
| Beta | 0.22 |
| Outstanding Shares | 192,959,000 |
Return
| Return on Equity | 1.15% |
|---|---|
| Return on Assets | 0.62% |
| Return on Invested Capital | 0.76% |
Valuation & Multiples
| P/E Ratio | 153.97 |
|---|---|
| PEG | -189.18 |
| Price to Sales | 3.36 |
| Price to Book Ratio | 1.78 |
| Enterprise Value to Revenue | 4.43 |
| Enterprise Value to EBIT | 198.04 |
| Enterprise Value to Net Income | 206 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$-0.05
Consensus analyst estimateRevenue Estimate
$1.02 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 22, 2027
EPS Estimate
$1.61
Consensus analyst estimateRevenue Estimate
$1.10 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 36.98% |
|---|---|
| Total Calls | 1,196▼ 99.93% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.55%▼ 97.79% |
|---|---|
| Total Invested | $409.69M▼ 96.34% |
| Investors Holding | 158▼ 430.00% |
About Biomarin Pharmaceutical Inc.
3,221 employees
CEO: Jean-Jacques Bienaime
BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic solutions for individuals grappling with severe and life-threatening rare diseases. Its array of market-ready products features Vimizim, an ...